Tramadol hydrochloride is a centrally acting synthetic analgesic with a dual mechanism of action. Tramadol and its Odesmethyl metabolite (M1) bind to opioid receptors, with M1 having a 200-fold higher affinity for binding to these receptors. Tramadol has also been shown to inhibit the uptake of norepinephrine and serotonin, suggesting that its antinociceptive activity is mediated by both opioid and nonopioid mechanisms. In patients with diabetic neuropathy, therapy with oral tramadol resulted in low pain scores and high painrelief scores. Tramadol produced effective analgesia with minimal adverse effects in cancer patients with chronic pain.
Tramadol is also a useful alternative in patient-controlled epidural analgesia when patients cannot receive combined spinal? epidural analgesia for labor pains. There are some clinical situations in which tramadol must be combined with other drugs, such as for patients with postoperative pain who require both a painkiller and an antibiotic or when tramadol is used as an adjunct to analgesic-supplemented anesthesia for certain surgical procedures. In addition, patients receiving tramadol are likely to receive other i.v. medications concurrently. There may be a need for tramadol and other agents to be administered through the same intravenous line.
Tramadol can be administered by i.v. bolus injection and by i.v. infusion. The objective of this study was to investigate the compatibility of tramadol injection with different infusion solutions and in admixtures
No comments:
Post a Comment